Orum Therapeutics is a private biotech company located in Daejeon, Korea, and Cambridge, Massachusetts. Based on the groundbreaking work by Prof Yong-Sung Kim at Ajou Univ, we are developing a novel class of therapeutic antibodies to bring new medicines to patients with unmet medical needs, and leverage our unique cell-penetrating antibody platform, which inhibits intracellular protein drug targets that are considered undruggable by small molecules or current antibody therapeutics.
Orum (오름) means ‘ascent’ in Korean, and it represents to us the idea of climbing or moving upwards. In 2016, we were founded with the goal of discovering the antibodies against undruggable targets such as RAS. RAS has been considered a highly-validated cancer drug target, but also has a reputation of being highly undruggable.
We named our company Orum, because we believe that inhibiting undruggable targets with antibody drugs is akin to climbing K2, one of the most dangerous mountains in the world. K2 was insurmountable for nearly 100 years, until its first climbers used oxygen tanks in 1952. We believe Orum possesses the ‘oxygen tank,’ but requires further perseverance, determination and teamwork in order to complete our ascent.
Our vision is a world where undruggable targets are no longer undruggable, so that no patient suffers from diseases because antibodies cannot penetrate cells.